The firm lowered its price target to $94 from $112 on shares of the Foster City, CA-based biopharmaceutical company.
Leerink is "outright bearish" on Gilead's Hepatitis C treatments, TheFly reports. Revenue from the company's Hepatitis C business will "decline faster and farther" than analysts expect, the firm said.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Gilead's strengths such as its notable return on equity, attractive valuation levels and expanding profit margins outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: GILD
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.